Clinical trial registry record

ReNEW: a clinical trial investigating the efficacy and safety of elamipretide in subjects who have dry age-related macular degeneration (Dry AMD)

A registered Phase III study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase iii study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated November 5, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
ISRCTN59733193
Last registry update
November 5, 2025
Status
Recruiting
Phase
Phase III
Sponsor
Stealth BioTherapeutics (United States)
Enrollment
313
Countries
United States of America, United Kingdom, New Zealand, Czech Republic, Germany, Hungary, Italy, Spain
Match confidence
100%
Source feed
ISRCTN Registry
Automated source synopsis

A registered Phase III study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase III
Study design
Interventional
Evidence population
Human clinical study registration
Participants
313
Population
All · Adult
Duration
2024-05-30 to 2027-08-01
Intervention
Elamipretide [D-Arginyl-2’,6’-dimethyl-L-tyrosyl- L –lysyl- L –phenylalaninamide (free base)]; Drug
Comparator
Not reported
Outcomes measured
The rate of change in the macular area of photoreceptor loss (defined as an Ellipsoid Zone-Retinal Pigment Epithelium t…; 1. Rate of change in the macular area of photoreceptor loss (defined as an EZ-RPE thickness of 0μm) assessed by SD-OCT…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase IIIA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as Interventional.

Automated source check 98% · update recency 85%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON